Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Receivables (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Receivables for 15 consecutive years, with $368000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Receivables fell 47.73% to $368000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $368000.0, a 47.73% decrease, with the full-year FY2023 number at $680000.0, down 65.53% from a year prior.
  • Receivables was $368000.0 for Q3 2025 at NovaBay Pharmaceuticals, down from $704000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $2.6 million in Q2 2023 to a low of $300000.0 in Q1 2022.
  • A 5-year average of $1.2 million and a median of $1.0 million in 2021 define the central range for Receivables.
  • Peak YoY movement for Receivables: soared 511.67% in 2023, then tumbled 79.15% in 2024.
  • NovaBay Pharmaceuticals' Receivables stood at $1.7 million in 2021, then grew by 16.95% to $2.0 million in 2022, then plummeted by 65.53% to $680000.0 in 2023, then grew by 3.53% to $704000.0 in 2024, then plummeted by 47.73% to $368000.0 in 2025.
  • Per Business Quant, the three most recent readings for NBY's Receivables are $368000.0 (Q3 2025), $704000.0 (Q3 2024), and $547000.0 (Q2 2024).